Volume 17, Issue 9, Pages 1203-1216 (September 2016) 30-day mortality after systemic anticancer treatment for breast and lung cancer in England: a population-based, observational study  Michael Wallington, BA, Emma B Saxon, PhD, Martine Bomb, PhD, Rebecca Smittenaar, PhD, Matthew Wickenden, BSc, Sean McPhail, PhD, Jem Rashbass, PhD, David Chao, FRCP, John Dewar, FRCR, Prof Denis Talbot, PhD, Michael Peake, FRCP, Prof Timothy Perren, MD, Charles Wilson, MD, Prof David Dodwell, MD  The Lancet Oncology  Volume 17, Issue 9, Pages 1203-1216 (September 2016) DOI: 10.1016/S1470-2045(16)30383-7 Copyright © 2016 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY NC-ND license Terms and Conditions

Figure 1 Study profile for our analyses in this report NSCLC=non-small cell lung cancer. *The number of excluded patients with NSCLC is not shown here, as the excluded patient group was not traced in the National Cancer Registration and Analysis Service for additional morphology data. The Lancet Oncology 2016 17, 1203-1216DOI: (10.1016/S1470-2045(16)30383-7) Copyright © 2016 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY NC-ND license Terms and Conditions

Figure 2 Funnel plot of variation in risk-adjusted 30-day mortality in patients with breast cancer given systemic anticancer therapy with curative intent, by hospital trust Each circle represents a separate hospital trust; blue and red circles represent outliers beyond the 95% and 99·8% confidence interval boundaries that are represented as grey lines. Red line shows national risk-adjusted 30-day mortality rate. The Lancet Oncology 2016 17, 1203-1216DOI: (10.1016/S1470-2045(16)30383-7) Copyright © 2016 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY NC-ND license Terms and Conditions

Figure 3 Funnel plot of variation in risk-adjusted 30-day mortality in patients with breast cancer given systemic anticancer therapy with palliative intent, by hospital trust Each circle represents a separate hospital trust; blue and red circles represent outliers beyond the 95% and 99·8% confidence interval boundaries that are represented as grey lines. Red line shows national risk-adjusted 30-day mortality rate. The Lancet Oncology 2016 17, 1203-1216DOI: (10.1016/S1470-2045(16)30383-7) Copyright © 2016 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY NC-ND license Terms and Conditions

Figure 4 Funnel plot showing variation in risk-adjusted 30-day mortality in patients with non-small cell lung cancer given systemic anticancer therapy with curative intent, by hospital trust Each circle represents a separate hospital trust; blue and red circles represent outliers beyond the 95% and 99·8% confidence interval boundaries that are represented as grey lines. Red line shows national risk-adjusted 30-day mortality rate. The Lancet Oncology 2016 17, 1203-1216DOI: (10.1016/S1470-2045(16)30383-7) Copyright © 2016 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY NC-ND license Terms and Conditions

Figure 5 Funnel plot showing variation in risk-adjusted 30-day mortality in patients with non-small cell lung cancer given systemic anticancer therapy with palliative intent, by hospital trust Each circle represents a separate hospital trust; blue and red circles represent outliers beyond the 95% and 99·8% confidence interval boundaries that are represented as grey lines. Red line shows national risk-adjusted 30-day mortality rate. The Lancet Oncology 2016 17, 1203-1216DOI: (10.1016/S1470-2045(16)30383-7) Copyright © 2016 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY NC-ND license Terms and Conditions